Clinical trials: Sodium Glucose Co-Transporter 2 Inhibitors
Lupus Nephritis
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.
- Trial name
- NCT06113900
- Testing
- Dapagliflozin 10mg Tab orally once daily
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Inflammation
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
- Trial name
- EFSII (NCT06812429)
- Testing
- Dapagliflozin (DAPA)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Diabetic Foot Ulcer
SGLT-i Use in Diabetic Foot Ulcer Disease
Background: People with diabetes and either current or previous diabetic foot ulcer disease (DFUD) are at very high risk for adverse cardiovascular events including heart attacks and strokes.
- Trial name
- NCT06000722
- Testing
- eDelphi method
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Leicester